Previda®-DX is a personalized test tailored to patients’ specific genetic background. Patients interested in Previda®-DX are required to provide a report of their genetic records to assess if the test can be performed. After reviewing the patient’s gene report, scientists at Progenesis design a test to detect the mutation or rearrangement. Our team of laboratory technicians will optimize the test by using parental DNA to confirm the abnormality. The final test is performed on a biopsy from the embryo and includes testing for the specific mutation and/or chromosomal rearrangement in the embryo (PGT-M and PGT-SR) as well as 24-chromosome screening for aneuploidies (PGT-A).
Progenesis is the first company in the U.S. to use next generation sequencing (NGS) technology for preimplantation genetic diagnosis (PGT-M and PGT-SR). NGS is far superior to the current industry standard (real-time PCR).
NGS combines the power of single mutation detection and complete 24-chromosome screening. In addition, NGS offers the most accurate and sensitive technology to screen for unbalanced translocation events which are difficult to detect using traditional PCR and fluorescent in-situ hybridization based techniques.